论文部分内容阅读
目的:探讨干扰素及阴道用乳酸菌素胶囊治疗宫颈HR一HPV感染及宫颈病变的可行性,为防治宫颈癌提供科学依据。方法:收集于2012年6月至2014年12月在新疆生产建设兵团医院就诊的年龄在30-59岁之间妇女均经HC-2检查感染高危型HPV,同时经宫颈液基细胞学检查及阴道镜活检病理检查确诊为宫颈内瘤变Ⅰ级(CINⅠ)[1]的门诊随访患者167例。研究中纳入治疗组98例,对照组69例,治疗组用干扰素栓及阴道用乳酸菌素胶囊隔日阴道放药,两药间隔开,月经期停药,每月用药共20日,月经期停药;一组随访。结果:治疗组98例患者除改其他治疗或失访9例外,随访第4月,CINⅠ的消退率40.8%,HR-HPV消退率61.2%;随访第6月,CINⅠ的消退率40.8%,HR-HPV消退率61.2%;随访第12月,CINⅠ的消退率70.2%,HR-HPV消退率86.2%;随访第24月,CINⅠ的消退率88.8%,HR-HPV消退率92.1%。对照组随访第4月,CINⅠ的消退率20.3%,HR-HPV消退率29%;随访第6月,CINⅠ的消退率28.7%,HR-HPV消退率45.5%;随访第12月,CINⅠ的消退率53.3%,HR-HPV消退率60%;随访第24月,CINⅠ的消退率70.4%,HR-HPV消退率75.9%。结果在2年内大部分患者HR-HPV可自然清除,CINⅠ大部分逆转,而保持阴道内环境稳定,应用干扰素的抗病毒作用可明显加速HR-HPV的清除和CINⅠ逆转。结论:阴道用乳杆菌联合干扰素治疗合并HPV感染的CINI是一种疗效显著、使用方便的治疗方法,值得临床推广应用。
Objective: To investigate the feasibility of interferon and vaginal lactic acid bacteria capsules in the treatment of cervical HR-HPV infection and cervical lesions, to provide a scientific basis for the prevention and treatment of cervical cancer. Methods: From June 2012 to December 2014, women aged 30-59 years old who were treated at the Xinjiang Production and Construction Corps Hospital were infected by HC-2. High-risk HPV was detected by cervical liquid-based cytology Colposcopy biopsy pathology confirmed diagnosis of cervical intraepithelial neoplasia grade (CIN Ⅰ) [1] outpatient follow-up of 167 patients. The study included 98 patients in the treatment group and 69 in the control group. The patients in the treatment group were treated with interferon suppository and vaginal lactic acid bacteria capsule every other day for vaginal discharge. The two drugs were separated from each other and menstruation was stopped. The medication was monthly for 20 days and menstruation stopped Medicine; a group of follow-up. Results: In 98 cases of treatment group, except for the other treatment or no-follow-up, 9 cases of CINⅠdiagnosis rate was 40.8% and HR-HPV regression rate was 61.2% at the 4th month of follow-up. -HPV regression rate was 61.2%. At the 12th month after follow-up, the rate of regression of CINⅠwas 70.2% and the rate of HR-HPV regression was 86.2%. At 24th month of follow-up, the regression rate of CINⅠwas 88.8% and the HR-HPV regression rate was 92.1%. The control group was followed up for 4 months, the rate of CINⅠdiagnosis was 20.3% and that of HR-HPV was 29%. At the 6th month of follow-up, the rate of regression of CINⅠwas 28.7% and the rate of HR-HPV was 45.5% The rate of HR-HPV subsided was 60%. At 24th month of follow-up, the rate of regression of CINⅠwas 70.4% and the rate of HR-HPV subsidence was 75.9%. Results HR-HPV could be cleared naturally in most patients within 2 years, most of CIN I reversed, and the vaginal environment was stable. The anti-virus effect of interferon could obviously accelerate HR-HPV clearance and CIN I reversal. Conclusion: The treatment of vaginal Lactobacillus combined with interferon CINI combined with HPV infection is a curative effect, easy to use and is worthy of clinical application.